Skip to main content
Equibles
NVCR logo

NVCR · NovoCure Ltd

Track NVCR — free

Use NVCR with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about NVCR

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$16.95 -0.43 (-2.47%) At close · Aug 14
Market Cap
$1.97B
Shares
116.45M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$16.95 Open$17.23 Day$16.80–17.23 52W close$10.03–19.99 Avg vol 30d1.6M Short int10.1M · 8.7% float · 4.9d Short vol74% Last earningsJul 23, 2026 DataJan 2020–Aug 2026 Filing10-Q · Jul 23

Up next

Next earnings call
Oct 22, 2026 Est · unconfirmed · in 10 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Jul 23, 2026

AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Ask ALVIS about this →

      Equibles Rating

      blended score · not investment advice
      Overall
      Buy
      SellHoldBuy
      Technical Buy Momentum Very Strong Sentiment Neutral Fundamentals Excellent Quant / Vol Very High
      Market backdrop VIX 14.3 · calm Equity put/call 0.52
      Technical
      price trend
      Buy
      50 / 200-day cross No cross
      Price vs 200-day avg +22%
      above
      Price vs 50-day avg +3%
      above
      RSI (14) 53
      neutral
      MACD trend Positive
      52-week position 69%
      mid-range
      Volume (OBV) Confirms
      volume backs price
      Momentum
      relative strength
      Very Strong
      1-month return +6%
      trailing
      6-month return +54%
      trailing
      YTD return +31%
      this year
      Relative strength +41%
      vs S&P · 6-mo
      Sentiment
      smart money
      Neutral
      Trend (MA cross) No cross
      50d $16 › 200d $14 — 50d above 200d
      Institutional flow Distributing
      -6% holders QoQ · +29 funds added
      Insider flow Distributing
      Net -$939.7K over 90 days · 100% sells
      Short interest Falling
      8.71% of float · ▼ -11.5% MoM · 4.9 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr low
      211 holders — near 3-yr low, contrarian setup
      Squeeze score 55
      elevated · 0–100
      Fundamentals
      Excellent
      Revenue growth +8%
      Y/Y
      Gross margin 75%
      contracting
      EPS growth +22%
      Y/Y
      Free cash flow $-75.7M
      Balance sheet $93.4M
      net cash
      Quant / Vol
      risk profile
      Very High
      Volatility 80%
      annualized · 1-yr
      Max drawdown −33%
      past year
      ATR 5.6%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Guidance & track record

      Latest guidance · from the 8-K filed Jul 23, 2026
      Total net revenue · full year 2026 $710M – $725M
      Net revenue contribution from Optune Lua and Optune Pax · full year 2026 $20M – $30M
      Prior guidance period ended · from the Earnings Call filed Mar 31, 2025
      Import duties on 2025 cost of goods · 2025 $11M

      Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

      Technicals

      trend & momentum for long-term holders Buy
      0 · 4 · 3
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      +22% Bullish
      Price vs 50-day avg
      +3% Bullish
      RSI (14)
      53 Neutral
      MACD trend
      Positive Bullish
      52-week position
      69% Neutral
      Volume (OBV)
      Confirms Neutral
      Market signals — smart money & positioning
      Bearish · 2 of 6
      Trend (MA cross) No cross
      50d $16 › 200d $14 — 50d above 200d
      Institutional flow Distributing
      -6% holders QoQ · +29 funds added
      Insider flow Distributing
      Net -$939.7K over 90 days · 100% sells
      Short interest Falling
      8.71% of float · ▼ -11.5% MoM · 4.9 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr low
      211 holders — near 3-yr low, contrarian setup
      Price context
      position in its 52-week range
      Range low $10 Now $17 · 69% Range high $20
      vs 200-day avg +22% vs 50-day avg +3%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Key metrics

      the company's own KPIs, from written earnings releases and filings
      Metric Latest Period YoY
      Active patients on Optune Gio in France 471 Q2 2026 —
      Active patients on Optune Gio in Germany 637 Q2 2026 —
      Active patients on Optune Gio in Japan 553 Q2 2026 —
      Active patients on Optune Gio in other active markets 634 Q2 2026 —
      Active patients on Optune Gio in the U.S. 2,341 Q2 2026 —
      Active patients on Optune Lua in France 1 Q2 2026 —
      Active patients on Optune Lua in Germany 38 Q2 2026 —
      Active patients on Optune Lua in Japan 64 Q2 2026 —
      Active patients on Optune Lua in other active markets 5 Q2 2026 —
      Active patients on Optune Lua in the U.S. 99 Q2 2026 —
      Prescriptions for Optune Pax received in the quarter 418 Q2 2026 —
      Prescriptions for Optune Pax received 169 Q1 2026 —
      Active Optune Lua patients on therapy for the treatment of MPM 34 as of December 31, 2025 —
      Active Optune Lua patients on therapy for the treatment of NSCLC 122 as of December 31, 2025 —
      Optune Gio prescriptions received for the treatment of GBM 1,609 fourth quarter —
      Optune Lua prescriptions received for the treatment of MPM 27 fourth quarter —
      Optune Lua prescriptions received for the treatment of NSCLC 118 fourth quarter —
      Total Optune Lua prescriptions received 145 fourth quarter —

      Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

      Versus peers

      Medical Devices — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      NVCR
      NovoCure Ltd
      this stock
      		$1.97B +31.1% +8.3% — 8.7%
      ABT
      Abbott Laboratories
      		 $194.07B -11.2% +5.7% 31.2 1.3%
      SYK
      Stryker Corp
      		 $130.11B -3.5% +11.2% 35.2 2.2%
      MDT
      Medtronic plc
      		 $116.83B -5.0% +8.4% 24.5 1.4%
      BSX
      Boston Scientific Corp
      		 $75.11B -45.6% +12.5% 21.0 1.5%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Accumulating
      Holders
      211
      % held
      87.4%
      Net QoQ
      +1.2M sh
      Top holder
      FMR LLC
      Held Float
      View
      Held by Funds
      Fund positions
      82
      View
      Short & Settlement
      Short Interest Falling
      Shares short
      10.1M
      Days to cover
      4.9d
      Change
      -1.3M sh
      View
      Short Volume
      Short vol %
      74%
      As of
      Aug 14, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      161
      Value
      $2.9K
      As of
      Jun 15, 2026
      View
      Off-Exchange
      Off-exchange %
      46.3%
      Week of
      Jul 6, 2026
      Off-exch Lit
      View
      Smart Money
      Insider Trades Net selling
      Net (90d)
      -$939.7K
      Buyers / Sellers
      0 / 8
      Buyers Sellers
      View
      Congressional Trades Buy
      Member
      Marie Newman
      Amount
      $15.0K–$50.0K
      Traded
      Jul 2, 2021
      View
      Financials
      Financials
      Revenue (FY)
      $655.4M
      Net income (FY)
      $-136.2M
      EPS diluted
      $-1.22
      View
      Filings
      SEC Filings
      Latest
      8-K
      Filed
      Jul 23, 2026
      This year
      17
      View
      Proposed Sales
      Value
      $608.6K
      Shares
      39.1K
      Filed
      Jul 23, 2026
      View
      Earnings & Events
      Earnings Calls
      Last call
      Jul 23, 2026
      View

      Performance

      5D 20D 120D MTD YTD
      NVCR +3.4% +6.5% +54.4% +14.2% +31.1%
      SPY +0.4% +4.5% +13.8% +3.9% +13.9%
      vs SPY +3.0% +2.0% +40.6% +10.3% +17.2%
      Key facts CIK 1645113 CUSIP G6674U108 13F (30d) 222 filings 196 filers Visit website Investor relations

      Report a Problem

      Category
      Description
      Email (optional, for follow-up)